Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Blood ; 125(15): 2370-80, 2015 Apr 09.
Article in English | MEDLINE | ID: mdl-25655603

ABSTRACT

Although information about the molecular pathogenesis of Waldenström macroglobulinemia (WM) has significantly advanced, the precise cell of origin and the mechanisms behind WM transformation from immunoglobulin-M (IgM) monoclonal gammopathy of undetermined significance (MGUS) remain undetermined. Here, we undertook an integrative phenotypic, molecular, and genomic approach to study clonal B cells from newly diagnosed patients with IgM MGUS (n = 22), smoldering (n = 16), and symptomatic WM (n = 11). Through principal component analysis of multidimensional flow cytometry data, we demonstrated highly overlapping phenotypic profiles for clonal B cells from IgM MGUS, smoldering, and symptomatic WM patients. Similarly, virtually no genes were significantly deregulated between fluorescence-activated cell sorter-sorted clonal B cells from the 3 disease groups. Interestingly, the transcriptome of the Waldenström B-cell clone was highly different than that of normal CD25(-)CD22(+) B cells, whereas significantly less genes were differentially expressed and specific WM pathways normalized once the transcriptome of the Waldenström B-cell clone was compared with its normal phenotypic (CD25(+)CD22(+low)) B-cell counterpart. The frequency of specific copy number abnormalities [+4, del(6q23.3-6q25.3), +12, and +18q11-18q23] progressively increased from IgM MGUS and smoldering WM vs symptomatic WM (18% vs 20% and 73%, respectively; P = .008), suggesting a multistep transformation of clonal B cells that, albeit benign (ie, IgM MGUS and smoldering WM), already harbor the phenotypic and molecular signatures of the malignant Waldenström clone.


Subject(s)
B-Lymphocytes/pathology , Cell Transformation, Neoplastic/genetics , Monoclonal Gammopathy of Undetermined Significance/genetics , Waldenstrom Macroglobulinemia/genetics , B-Lymphocytes/metabolism , Cell Transformation, Neoplastic/pathology , Clone Cells , Flow Cytometry , Gene Dosage , Gene Expression Regulation, Neoplastic , Genomics , Humans , Immunoglobulin M/analysis , Monoclonal Gammopathy of Undetermined Significance/pathology , Mutation , Myeloid Differentiation Factor 88/genetics , Phenotype , Waldenstrom Macroglobulinemia/pathology
2.
Blood ; 124(8): 1300-3, 2014 Aug 21.
Article in English | MEDLINE | ID: mdl-24876564

ABSTRACT

Solitary plasmacytoma represents a heterogeneous group of patients; approximately half develop multiple myeloma (MM) in 2 or 3 years, whereas others remain disease-free at 10 years. By definition, these patients do not have morphologic bone marrow (BM) plasma cell (PC) infiltration. Here, we investigated whether sensitive BM evaluation of patients with solitary bone plasmacytoma (SBP; n = 35) and extramedullary plasmacytoma (EMP; n = 29) through multiparameter flow cytometry (MFC) would unravel the presence of clonal PCs in otherwise disease-free BM, and whether BM clonality predicted higher risk of progression. BM clonal PCs were detected in 17 of 35 SBP (49%) and 11 of 29 EMP (38%) patients. Seventy-one percent of flow-positive vs only 8% of flow-negative SBP patients evolved to MM (median time to progression of 26 months vs not reached; hazard ratio, 17.4; P < .001). No significant differences were observed among EMP cases. Our results highlight the importance of MFC for sensitive BM evaluation of SBP patients, to predict risk of developing treatment-requiring MM and to plan disease monitoring.


Subject(s)
Bone Neoplasms , Flow Cytometry , Multiple Myeloma , Plasmacytoma , Adult , Aged , Aged, 80 and over , Bone Neoplasms/metabolism , Bone Neoplasms/mortality , Bone Neoplasms/pathology , Bone Neoplasms/therapy , Female , Follow-Up Studies , Humans , Male , Middle Aged , Multiple Myeloma/metabolism , Multiple Myeloma/mortality , Multiple Myeloma/pathology , Multiple Myeloma/therapy , Neoplasm Staging/methods , Plasmacytoma/metabolism , Plasmacytoma/mortality , Plasmacytoma/pathology , Plasmacytoma/therapy , Retrospective Studies , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...